QiagenQGEN
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,700
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $32.9M | Put options by funds: $22.5M
33% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 4 (+1) [Q1 2025]
0.15% less ownership
Funds ownership: 66.45% [Q4 2024] → 66.3% (-0.15%) [Q1 2025]
9% less funds holding
Funds holding: 322 [Q4 2024] → 293 (-29) [Q1 2025]
12% less capital invested
Capital invested by funds: $6.6B [Q4 2024] → $5.78B (-$815M) [Q1 2025]
34% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 67
59% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 175
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
B of A Securities Derik De Bruin | 5%upside $53 | Buy Maintained | 26 Jun 2025 |
Barclays Luke Sergott | 9%upside $55 | Overweight Initiated | 24 Jun 2025 |
Financial journalist opinion
Based on 4 articles about QGEN published over the past 30 days
